Skip to main content

Table 2 ASMs characteristics and vitamin D status

From: Hypovitaminosis D and risk factors in pediatric epilepsy children

ASMs characteristics Total subjects
n = 138
Vitamin D
sufficiency
25(OH)D
>  30 ng/ml
n = 40
Hypovitaminosis D
25(OH)D
≤ 30 ng/ml
n = 98
P-value
Monotherapy
  no 71(51.4%) 24(33.8%) 47(66.2%) 0.201
  yes 67(48.6%) 16(23.9%) 51(76.1%)  
Duration of ASMs used
  ≤ 2 years 33(23.9%) 15(45.4%) 18(54.5%) 0.017*
  >  2 years 105(76.1%) 25(23.8%) 80(76.2%)  
Enzyme-inducer ASMs (CBZ,PB,PHT)
  no 112(81.1%) 34(30.4%) 78(69.6%) 0.461
  yes 26(18.9%) 6(23.1%) 20(76.9%)  
Enzyme-inhibitor ASMs (VPA)
  no 85(61.6%) 20(23.5%) 65(76.5%) 0.074
  yes 53(38.4%) 20(37.7%) 33(62.3%)  
BZD and Newer ASMs
  no 25(18.1%) 6(24%) 19(76%) 0.545
  yes 113(81.9%) 34(30.1%) 79(69.9%)  
Levetiracetam
  no 58(42.1%) 16(27.6%) 42(72.4%) 0.758
  yes 80(57.9%) 24(30%) 56(70%)  
Topiramate
  no 85(61.6%) 26(30.6%) 59(69.4%) 0.599
  yes 53(38.4%) 14(26.4%) 39(73.6%)  
Topiramate dosage
  <  5 mg/kg/day 17(32.1%) 7(41.2%) 10(58.8%) 0.092
  ≥ 5 mg/kg/day 36(67.9%) 7(19.4%) 29(80.6%)  
  1. ASMs anti-seizure medications; CBZ Carbamazepine; PB Phenobarbital; PHT Phenytoin; VPA Valproate; BZD Benzodiazepine
  2. *p-value significant at < 0.05